Table 2.

Case Reports of Brincidofovir Use in Humans With Poxvirus Infections

Case	Age (Years), Sex	Virus	Risk Factor	Site of Infection	Brincidofovir Dose/Frequency	Duration of Brincidofovir	Additional Therapies	Outcome	Reference
1	Adult M	Vaccinia	Acute myeloid leukemia diagnosis after smallpox vaccine	Skin (progressive vaccinia)	100 mg orally once a week (initial dose 200 mg)	6 weekly doses	Intravenous vaccinia immunoglobulin, tecovirimat	Complete resolution	[67]
2	30–40, M	Mpox	Travel to endemic area	Skin	200 mg orally	One dose	None	Complete resolution	[20]
3	30–40, M	Mpox	Travel to endemic area	Skin, deep soft tissue abscesses	200 mg orally once a week	Two doses	Abscess drainage	Complete resolution	[20]
4	30–40, F	Mpox	Exposure to patient with mpox	Skin, conjunctivitis, subungual lesion	200 mg orally once a week	Two doses	None	Complete resolution	[20]
5	17, M	Cowpox	Exposure to pet cat, renal transplant recipient	Skin, tonsils, disseminated	Not reported	Not reported	Cidofovir prior to brincidofovir, vaccinia immunoglobulin	Progression and death	[81]

Abbreviations: F, female; M, male.